# ASX RELEASE

28 September 2026

## 2026 Notice of Annual General Meeting

Acusensus Limited (ASX:ACE) (**Acusensus**) today issues its 2026 Notice of Annual General Meeting and Explanatory Statement (**Notice**). The Notice, a sample proxy form and the communication sent to shareholders regarding the Notice are attached. The Notice is also available on the Acusensus website.

The Annual General Meeting will be held on Wednesday 28 October 2026 at 10:30am (Sydney time) at Cliftons Sydney Margaret Street, 13/60 Margaret Street, Sydney NSW 2000, Australia (**Meeting**). The Notice includes further information on the business of the Meeting and how shareholders may participate in the Meeting.

The Notice and proxy forms will be despatched to shareholders today.

END

**Enquiries**


Anita Chow
Chief Financial Officer, Acusensus Limited
+61 408 261 554
Email: investor-relations@acusensus.com

Simon Hinsley
Investor and Media Relations
+61 401 809 653
Email: simon@nwrcommunications.com.au


This announcement is authorised by the Board of Acusensus Limited.

**About Acusensus**

Acusensus is a technology company that was founded in 2018 with a mission to design and develop artificial intelligence enabled road safety solutions. Collaborating with governments and commercial stakeholders to tackle distracted driving globally is Acusensus' first priority. Acusensus has pioneered intelligent solutions that provide anywhere, anytime digital evidence that can be used in conjunction with law enforcement to drive behavioural change and improve road safety. Acusensus technology is used to detect and provide prosecutable evidence of distracted driving (mobile phone use), seatbelt compliance, speeding, railway crossing compliance and the monitoring of vehicles of interest.

Leveraging AI and sensing expertise, Acusensus also provides technology that protects workers in live traffic environments. The Forsite by Acusensus road worker safety system integrates roadside sensors, connected wearables and real time analytics to give crews early warning of approaching vehicle risks, delivering the vital seconds needed to avoid harm while generating data that helps make worksites safer over time.

Acusensus listed on the Australian Securities Exchange in January 2023. Acusensus is headquartered in Melbourne, Australia, with offices in Sydney, Brisbane, Perth, Auckland (New Zealand), Christchurch (New Zealand), London (United Kingdom), Las Vegas Nevada (United States) and Hartford Connecticut (United States).

# 2026 NOTICE OF ANNUAL GENERAL MEETING

ACUSENSUS LIMITED | ACN 625 231 941

# ANNUAL GENERAL MEETING OF ACUSENSUS LIMITED (ACN 625 231 941) (COMPANY)

## LETTER FROM THE CHAIR

Dear Shareholders,

On behalf of the Directors of Acusensus Limited, it is my pleasure to invite you to join our 2026 Annual General Meeting, which will take place on Wednesday, 28 October 2026 at 10:30am (Sydney time) at Cliftons Sydney Margaret Street, 13/60 Margaret Street, Sydney NSW 2000, Australia.

If you cannot attend in person, you are invited to watch the live webcast online and can register to do this via the instructions in the Notice of Meeting. If you choose to watch the meeting via the webcast, any proxy appointments and questions will need to be submitted prior to the meeting by following the instructions in the Notice of Meeting. Shareholders who watch the Meeting online will not be able to vote or participate in the discussions at the Meeting.

At the Annual General Meeting, Acusensus' Managing Director and CEO, Alexander Jannink, and I will update shareholders on the performance of Acusensus, including on some of the important achievements over the 2026 financial year. Further information on Acusensus' financial performance and operations is included in the 2026 Annual Report, which can be accessed on the Acusensus Investor Centre website at investors.acusensus.com/investor-centre/ or via the ASX market announcements platform.

Acusensus was founded to design and develop artificial intelligence-enabled road safety solutions that drive behavioural change and reduce road trauma globally. In the past year, our dedicated and talented team has achieved remarkable progress toward that vision. We have continued our transition into a multi-jurisdictional, multi-offence technology provider, which has included the completion of a nationwide rollout of our mobile speed camera contract in New Zealand, alongside our first major statewide automated work-zone speed contract in the United States with the Connecticut Department of Transportation. International business now contributes 27% of group revenues, up from 7% a year ago, and we continue to invest in the United Kingdom, Europe, and the United States. In Australia, our government customers deepened their use of our platforms through new multi-function enforcement contracts in Western Australia and a further expansion of our transportable fleet in Queensland. We also commercially launched our worker safety business, Forsite, signing long-term agreements with Tier-1 infrastructure and construction enterprises for the deployment of our pioneering roadside worker safety technology.

The Annual General Meeting is an important opportunity for shareholders to vote on matters that are important to you and for the Board to hear from you. The Board encourages you to vote on the resolutions put before the Meeting and to ask questions, as per the instructions in the accompanying Notice of Meeting.

I look forward to welcoming you to our Annual General Meeting and thank you for your continued support of Acusensus.

Yours faithfully

**Ravin Mirchandani**
Co-Founder and Chair
Acusensus Limited



# NOTICE OF ANNUAL GENERAL MEETING OF ACUSENSUS LIMITED (ACN 625 231 941) (COMPANY)

NOTICE is given that the Annual General Meeting of Shareholders of the Company will be held on Wednesday, 28 October 2026 at 10:30am (Sydney time) at Cliftons Sydney Margaret Street, 13/60 Margaret Street, Sydney NSW 2000, Australia (Meeting).

The Company confirms that this document complies with the notice of meeting content requirements set out in the Listing Rules. On the basis of this confirmation, ASX has not objected to this document under Listing Rule 15.1.4.

This Notice of Annual General Meeting (Notice of Meeting or Notice) is an important document and should be read in its entirety. The Explanatory Statement accompanying this Notice of Meeting provides additional information on matters to be considered at the Meeting and instructions on how to participate in the Meeting. The Proxy Form and Explanatory Statement form part of this Notice of Meeting.

Shareholders can attend the Meeting in person. If you cannot attend in person, you are invited to watch the live webcast online. You can register in advance to watch the webcast of the Meeting via this Zoom link: https://us02web.zoom.us/webinar/register/WN_zOmlI2TESPGIZ8B9w56Clg. Shareholders who watch the Meeting online will not be able to vote or participate in the discussions at the Meeting. Shareholders who do not attend in person can submit questions in advance of the Meeting or vote by appointing a proxy. For the appointment of a proxy to be effective, a Proxy Form must be completed, signed and received by no later than 10:30am (Sydney time) on Monday, 26 October 2026.

Terms and abbreviations used in this Notice of Meeting will, unless the context requires otherwise, have the meaning given to them in the Glossary in Schedule 1.

## Items of Business of the Meeting

### Item 1: Chair's address

### Item 2: Presentation from Managing Director and CEO

### Item 3: Annual Report

### Item 4: Resolutions

- Ordinary resolutions
- Special resolutions

## Item 3: Annual Report

To receive and consider the Financial Report, the Directors' Report and the Auditor's Report contained within the Company's Annual Report for the year ended 30 June 2026.

Note that Shareholders are not required to approve these reports. Accordingly, no resolution is required for this item of business and no vote will be held on this item.

## Item 4: Resolutions

## Ordinary Resolutions

### Resolution 1: Remuneration Report (non-binding resolution)

To consider and, if thought fit, pass the following as a non-binding Ordinary Resolution of the Company:

> *"That the Remuneration Report, as set out in the Directors' Report for the financial year ended 30 June 2026, be adopted."*

Note that the Remuneration Report is set out in the Directors' Report and is included within the Company's 2026 Annual Report. In accordance with section 250R of the Corporations Act, the outcome of the vote on this resolution will be advisory only and will not bind the Directors or the Company.

Note that a voting prohibition applies to this resolution (see the Explanatory Statement for Resolution 1 for details).

### Resolution 2: Re-election of Independent Non-Executive Director, Mr Michael Giuffrida

To consider and, if thought fit, pass the following as an Ordinary Resolution of the Company:

> *"That Mr Michael Giuffrida, who was appointed as a Director on 9 October 2023, retires in accordance with clause 15.4.3 of the Constitution and ASX Listing Rule 14.4, and being eligible for re-election under clause 15.4.4 of the Constitution, be re-elected as a Director."*

### Resolution 3: Grant of Performance Rights to Managing Director and CEO, Mr Alexander Jannink

To consider and, if thought fit, pass the following as an Ordinary Resolution of the Company:

> *"That, for the purpose of ASX Listing Rule 10.14 and for all other purposes, approval be given to grant 217,213 Performance Rights under the Company's Equity Incentive Plan to the Managing Director and CEO of the Company, Mr Alexander Jannink (or his nominee), in respect of the financial year ending 30 June 2027 pursuant to the terms of the Equity Incentive Plan described in the Explanatory Statement accompanying this Notice."*

Note that voting exclusions apply to this resolution (see Explanatory Statement for Resolution 3 for details).

### Resolution 4: Approval of Increase to Non-Executive Directors' Fee Pool

To consider and, if thought fit, pass the following as an Ordinary Resolution of the Company:

> *"That, for the purposes of ASX Listing Rule 10.17 and article 15.9.1 of the Constitution and for all other purposes, approval be given to increase the maximum aggregate amount of fees that may be paid to all non-executive directors of the Company from $350,000 per annum to $600,000 per annum, with effect from the date this Resolution is passed."*

Note that voting exclusions apply to this resolution (see Explanatory Statement for details).

## Special Resolutions

### Resolution 5: Renewal of Proportional Takeover Bid Provisions in the Constitution

To consider and, if thought fit, pass the following as a Special Resolution of the Company:

*"That, for the purposes of section 648G(4) of the Corporations Act and for all other purposes, approval be given to renew the proportional takeover bid approval provisions contained in clause 27 of the Constitution for a period of three years with effect from the conclusion of the Meeting."*

### Resolution 6: Approval of 10% Additional Placement Capacity under ASX Listing Rule 7.1A

To consider and, if thought fit, pass the following as a Special Resolution of the Company:

*"That, for the purpose of ASX Listing Rule 7.1A and for all other purposes, approval be given for the issue of Equity Securities of up to 10% of the issued capital of the Company (at the time of issue) calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 and on the terms and conditions set out in the Explanatory Statement included in the Notice of Meeting."*

## Entitlement to Vote

The Directors have determined pursuant to regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders of the Company as at 7:00pm (Sydney time) on Monday, 26 October 2026 (Entitlement Time). This means that if you are not the registered holder of Shares at the Entitlement Time, you will not be entitled to attend and vote at the Meeting.

Voting on all resolutions will be determined by a poll at the Meeting.

## Annual Report

The Company's 2026 Annual Report can be accessed on the Acusensus Investor Centre website at investors.acusensus.com/investor-centre/ or via the ASX market announcements platform.

## Attendance at the Meeting

### Attendance at the venue

The venue for the Meeting is Cliftons Sydney Margaret Street, 13/60 Margaret Street, Sydney NSW 2000, Australia.

Shareholders are encouraged to arrive at the Meeting venue from 30 minutes prior to the start of the Meeting to allow adequate time for registration. Shareholders should bring their Shareholder Reference Number (SRN) or Holder Identification Number (HIN) to assist with registration.

If you do not plan to attend the Meeting in person, you are encouraged to complete and return the Proxy Form by following the instructions within this Notice of Meeting. You can also watch the live webcast online in accordance with the instructions below. Shareholders who watch the Meeting online will not be able to vote or participate in the discussions at the Meeting.

### Viewing the Meeting via Webcast

If you are unable to attend the Meeting in person, you are invited to watch the live webcast online. You can register in advance to watch the webcast of the Meeting via the following Zoom link:

https://us02web.zoom.us/webinar/register/WN_zOmIl2TESPGIZ8B9w56Clg.

Shareholders who do not attend in person can submit questions in advance of the Meeting or vote by appointing a proxy.

# Proxies

## Voting by Proxy

A Shareholder entitled to attend the Meeting and vote is entitled to appoint a proxy to attend and vote on their behalf. A proxy does not need to be a Shareholder of the Company and can be a natural person over the age of 18 years or a body corporate. A body corporate appointed as a Shareholder's proxy may appoint a representative to exercise any of the powers the body corporate may exercise as a proxy at the Meeting. The representative must bring to the Meeting evidence of their appointment, including any authority under which the appointment is signed.

If a Shareholder has not directed their proxy how to vote, the proxy may vote as the proxy determines subject to applicable law. If a Shareholder appoints the Chair of the Meeting as proxy and does not direct the Chair how to vote on an item of business, the Chair will vote in accordance with the voting intention as stated in this Notice of Meeting, which is in favour of each of the proposed resolutions.

A Shareholder who is entitled to attend and vote at the Meeting is entitled to appoint not more than two proxies to attend and vote in place of a Shareholder. If the Shareholder appoints two proxies, the Shareholder may specify the proportion or number of votes each proxy is entitled to exercise. If no proportion or number of votes is specified, each proxy may exercise half of the Shareholder's votes. If the specified proportion or number of votes exceeds that which the Shareholder is entitled to, each proxy may exercise half of the Shareholder's votes. Any fractions of votes brought about by the apportionment of votes to a proxy will be disregarded. If you attend the Meeting after appointing a proxy, your proxy will be suspended and you will need to vote during the Meeting if you want your vote to count.

If you have directed a proxy to vote and they fail to attend the Meeting or they do not vote in accordance with your instructions, then, on a poll, the Chair of the Meeting will become your proxy and vote your proxies as directed by you.

## Proxy Voting by the Chair and other Key Management Personnel (KMP)

Voting exclusions apply in respect of Resolutions 1, 3 and 4 as set out in the Explanatory Statement below.

That means if you appoint a member of the KMP (other than the Chair) as your proxy, to ensure that your vote is included, you must direct them how to vote in respect of Resolutions 1, 3 and 4.

If you appoint the Chair of the Meeting as your proxy, you can direct him how to vote or you can choose not to indicate your voting intention. If the Chair is your proxy, either by appointment or by default, and you have not indicated your voting intention, you expressly authorise the Chair to exercise the proxy in respect of Resolutions 1, 3 and 4 even where these Resolutions are connected directly or indirectly with the remuneration of the Company's KMP. The Chair intends to exercise all available proxies in favour of all Resolutions, unless the Shareholder has expressly indicated a different voting intention.

## Appointment of a Proxy

For the appointment of a proxy to be effective, a Proxy Form must be completed, signed, lodged and received with the Company's share registry, MUFG Corporate Markets (AU) Limited by no later than 10:30am (Sydney time) on Monday, 26 October 2026 (Proxy Deadline). If signed by an attorney, the relevant original power of attorney or a certified copy must also be included with the Proxy Form (unless previously provided to MUFG Corporate Markets). Proxy Forms may be submitted in one of the following ways:

- Hand delivery to MUFG Corporate Markets (AU) Limited, Parramatta Square, Level 22, Tower 6, 10 Darcy Street, Parramatta NSW 2150, Australia (during business hours 9:00am - 5:00pm Monday to Friday).
- Mail to Acusensus Limited, C/- MUFG Corporate Markets (AU) Limited, Locked Bag A14, Sydney South NSW 1235 Australia.
- Fax to +61 2 9287 0309.
- Online at https://au.investorcentre.mpms.mufg.com. Once logged in, select the 'Voting' tab and follow the prompts to appoint a proxy. You will be taken to have signed your Proxy Form if you lodge it in accordance with the instructions given on the website.

Proxy Forms and powers of attorney must be received by the Proxy Deadline. Proxy Forms received after this time will be invalid.

## Shareholders

### Submitting Questions

Shareholders, their representatives and proxyholders will have the opportunity to ask questions in person at the Meeting when invited to do so by the Chair. Shareholders are also invited to submit questions relating to the business of the Meeting in advance. The Company requests that Shareholders submit any questions at least 48 hours prior to the Meeting using the following methods:

- logging into the Investor Centre at https://au.investorcentre.mpms.mufg.com. Once logged in, follow the prompts to ask a question. You will need your SRN or HIN to lodge your question; or
- emailing investor-relations@acusensus.com with a subject line indicating that the email relates to a question to be put to the Meeting.

Written questions to the Company's auditor in relation to the Auditor's Report or the conduct of the audit must be received by 5:00pm (Sydney time) on Wednesday, 21 October 2026.

The Chair of the Meeting reserves the right to moderate questions during the Meeting. Protocols for asking questions will be explained at the start of the Meeting, so that as many shareholders as possible have the opportunity to participate and a broad range of topics are addressed.

It is not uncommon for several shareholders to ask the same or very similar questions, so those questions may be aggregated. Time may not allow for all questions to be answered. To facilitate the orderly conduct of the Meeting, shareholders are requested to limit themselves to three questions for each Item of business.

Questions or comments that include defamatory or offensive language or concepts will not be answered.

### Joint Holders

If more than one joint holder of Shares is present at the Meeting (whether in person, by proxy or by attorney or corporate representative) and casts a vote, only the vote of the joint holder whose name appears first on the register will be counted.

### Corporate Representatives

Where a shareholding is registered in the name of a corporation, the corporate Shareholder may appoint a person to act as its representative to attend the Meeting by an appointment letter in accordance with section 250D of the Corporations Act. Please contact the Company's share registry, MUFG Corporate Markets (AU) Limited, if you have any questions on duly appointing a corporate representative.

## General Questions

If you have any queries regarding how to cast your vote or other procedural questions, please call the Company's share registry, MUFG Corporate Markets (AU) Limited, on 1300 554 474 or +61 1300 554 474 (from outside Australia) between 8:30am and 7:30pm (Sydney time).

Dated: 28 September 2026

By Order of the Board

Annie Mould
Company Secretary
Acusensus Limited

# EXPLANATORY STATEMENT

This Explanatory Statement has been prepared for the information of Shareholders in connection with the business to be conducted at the Annual General Meeting of the Company.

This Explanatory Statement should be read in conjunction with, and forms part of, the accompanying Notice of Meeting. The purpose of this Explanatory Statement is to provide information to Shareholders, and where applicable, to help them decide whether or not to pass the resolutions set out in the Notice of Meeting.

## Details

### Item 3: Annual Report

Section 317 of the Corporations Act requires the Company's Financial Report, Directors' Report and Auditor's Report for the financial year ended 30 June 2026 (contained in the Company's 2026 Annual Report) to be laid before the Company's 2026 Annual General Meeting.

The Financial Report contains the financial statements of the consolidated entity consisting of Acusensus Limited and its controlled entities.

A copy of the Company's 2026 Annual Report can be accessed on the Acusensus Investor Centre website at investors.acusensus.com/investor-centre/ or via the ASX market announcements platform. A printed copy of the Company's 2026 Annual Report has been sent only to those Shareholders who have elected to receive a printed copy.

The Chair of the Meeting will allow a reasonable opportunity at the Meeting for Shareholders to ask questions about the Company's 2026 Annual Report.

Shareholders will also be given a reasonable opportunity at the Meeting to ask the Company's auditor, BDO Audit Pty Ltd, questions about the conduct of its audit of the Company's Financial Report for the year ended 30 June 2026, the preparation and content of the Auditor's Report, the accounting policies adopted by the Company in its preparation of the financial statements and the independence of the auditor in relation to the conduct of the audit. The auditor is not obliged to provide written answers.

### Resolution 1: Remuneration Report (non-binding resolution)

Section 250R of the Corporations Act requires a listed company to put a resolution to shareholders to adopt its Remuneration Report for the relevant financial year. Shareholders are asked to adopt the Company's Remuneration Report.

The Company's Remuneration Report is set out in the Directors' Report which is included within the Company's 2026 Annual Report and can be found at pages 66 to 81.

The Remuneration Report:

- describes the policies behind, and the structure of, the remuneration arrangements of the Company and the link between the remuneration of certain members of the senior management team and the Company's performance;
- sets out the remuneration arrangements in place for each Director and for certain members of the senior management team; and

- explains the basis for remunerating non-executive Directors and certain members of the senior management team, including the Managing Director and CEO.

The vote on this resolution is advisory only and does not bind the Directors or the Company. However, the Board will consider any discussion on this resolution and the outcome of the vote when considering the future remuneration policies and practices of the Company.

### Voting Prohibition

In accordance with sections 250BD and 250R of the Corporations Act, a vote on Resolution 1 must not be cast:

- (in any capacity) by or on behalf of a member of the KMP details of whose remuneration are included in the Remuneration Report, or a Closely Related Party of such a member; or
- as a proxy for members of the KMP at the date of the Meeting, or KMP's Closely Related Parties.

However, a vote may be cast as proxy by such person if the vote is not cast on behalf of a person who is excluded from voting on Resolution 1, and:

- the person is appointed as a proxy by writing that specifies the way the proxy is to vote on Resolution 1; or
- the proxy is the Chair and the appointment of the Chair as proxy does not specify the way the proxy is to vote on Resolution 1, but expressly authorises the Chair to exercise the proxy even if Resolution 1 is connected with the remuneration of a member of the KMP.

### Directors' Recommendation

Noting that each Director has a personal interest in their own remuneration, the Directors unanimously recommend that Shareholders vote in favour of this resolution.

### Chair's Voting Intention

The Chair intends to vote all available proxies in favour of this non-binding resolution.

## Resolution 2: Re-election of Independent Non-Executive Director, Mr Michael Giuffrida

Clause 15.4.3 of the Company's Constitution provides that at each AGM, one-third of the Directors (except for the Managing Director) or, if their number is not three or a multiple of three, then the number nearest but not exceeding one-third, shall retire from office by rotation. The Directors to retire in every year shall be those who have been longest in office since their last election but as between persons who became Directors on the same day shall (unless they otherwise agree between themselves) be determined by lot. A retiring Director is eligible for re-election pursuant to clause 15.4.4 of the Company's Constitution.

ASX Listing Rule 14.5 also provides that an entity which has Directors must hold an election of Directors at each annual general meeting. Under this resolution, Mr Michael Giuffrida will retire at the end of this Meeting and, being eligible, seeks re-election as a Director of the Company.

The Board considers Mr Michael Giuffrida to be an independent director.

### About Mr Michael (Mike) Giuffrida

Mr Michael (Mike) Giuffrida was appointed as an Independent Non-Executive Director of the Company on 9 October 2023.

Mike is an Australian entrepreneur with over 25 years of experience. In 1997, he co-founded and was the CEO of a human resource technology company, Acendre Pty Ltd (now Hire Road Inc.). Acendre pioneered using the internet as a means of delivering enterprise 'software-as-a-service' to organisations with the release of the first online resume builder and first online applicant tracking system software to the Australian market, before evolving into the full online talent management space. Under Mike's leadership, Acendre subsequently established a presence in the US, including in the US Federal Government market. Mike then led a process to identify a majority growth investment partner for Acendre and the subsequent acquisition of a US-based HR technology company. At the end of 2019, Mike led a successful transition to a US-based CEO to head up Acendre's next phase of growth, which enabled Mike to return to Australia full-time with his family. Since his exit from Acendre, Mike has been supporting Australian technology companies in various capacities including as a Non-Executive Director, Operating Partner and in executive capacities.

Mike resides in Melbourne, Australia and holds a Bachelor of Engineering degree.

### Voting Threshold

Resolution 2 is an Ordinary Resolution, which requires it to be passed by a simple majority of the votes cast by Shareholders entitled to vote on the resolution.

### Directors' Recommendation

The Directors (with Mr Giuffrida abstaining) unanimously recommend that Shareholders vote in favour of this resolution.

In recommending Mr Giuffrida's re-election, the other Directors note that he is a senior executive who brings significant experience. Additionally, they recognise Mr Giuffrida's contributions as an experienced Remuneration & Nominations Committee Chair and his expertise and leadership in the governance of globally-minded, high-growth and innovative technology companies.

### Chair's Voting Intention

The Chair of the Meeting intends to vote all available proxies in favour of this resolution.

## Resolution 3: Grant of Performance Rights to Managing Director and CEO, Mr Alexander Jannink

The resolution is being put to Shareholders to obtain approval for the grant of Performance Rights to Mr Alexander Jannink, Managing Director and CEO (or his nominee). The proposed grant of 217,213 Performance Rights relates to the long-term variable component of Mr Jannink's remuneration package for FY27 and is to be made under the Equity Incentive Plan. These Performance Rights constitute one component of Mr Jannink's total remuneration.

The terms and conditions of the Performance Rights are summarised in Schedule 2. If Shareholder approval is obtained, the Company will proceed to issue the Performance Rights to Mr Jannink. If Shareholder approval is not obtained, the Company will not be able to proceed with the issue of the Performance Rights, and the Company will have to consider alternative commercial means to incentivise Mr Jannink.

### ASX Listing Rule 10.14

ASX Listing Rule 10.14 requires an ASX-listed company to obtain shareholder approval for the acquisition of securities (including Performance Rights) under an employee incentive scheme by specified persons, which includes a director, subject to limited exceptions. Mr Jannink is a Director of the Company and, therefore, Shareholder approval is being sought for the purposes of ASX Listing Rule 10.14.1.

Exception 14 in ASX Listing Rule 7.2 provides that ASX Listing Rule 7.1 does not apply where shareholder approval for an issue of securities is obtained under ASX Listing Rule 10.14. This means that, if Shareholder approval is obtained under this resolution, any Performance Rights the subject of this Resolution, granted to Mr Jannink, and any new Shares issued to Mr Jannink in satisfaction of those Performance Rights, will be excluded from the calculation of the Company's utilisation of its 15% placement capacity under ASX Listing Rule 7.1 (i.e. the Company's capacity to issue further securities without Shareholder approval under ASX Listing Rule 7.1 will not be reduced by the number of these Performance Rights).

The Company has the discretion to satisfy Performance Rights either by issuing Shares, transferring Shares or paying the holder the market value of the Shares that the holder is entitled to.

### Information Required by ASX Listing Rule 10.15

The following information is provided to Shareholders in connection with the resolution:

- the Performance Rights will be issued under the Equity Incentive Plan to Mr Jannink (or his nominee);
- Mr Jannink falls into the category stipulated by ASX Listing Rule 10.14.1 by virtue of being a Director of the Company;
- 217,213 Performance Rights will be issued to Mr Jannink if Shareholder approval is received for this Resolution;
- Mr Jannink's total remuneration package for the financial year ended 30 June 2026 (FY26) was $892,787 as set out in the Company's 2026 Annual Report. Mr Jannink's remuneration for the current financial year will continue to consist of a base salary and variable components relating to his STI and LTI outcomes, which include fixed annual remuneration of $530,000 per annum (including superannuation); STI (at risk) up to 30% of fixed annual remuneration; and LTI (at-risk) up to 50% of fixed annual remuneration. This resolution is not seeking approval for the total remuneration of the Managing Director and CEO, rather it relates to the issue of securities to the Managing Director and CEO (as a Director) under the Equity Incentive Plan, which is one component of his total remuneration;
- Mr Jannink has previously been granted 225,275 Performance Rights for nil consideration under the Equity Incentive Plan as approved at the Company's 2025 Annual General Meeting and as set out in the Notice of Meeting dated 17 October 2025;
- Mr Jannink has previously been granted 320,834 Performance Rights for nil consideration under the Equity Incentive Plan as approved at the Company's 2024 Annual General Meeting and as set out in the Notice of Meeting dated 17 October 2024;
- Mr Jannink has previously been granted 281,573 Performance Rights for nil consideration under the Equity Incentive Plan as approved at the Company's 2023 Annual General Meeting and as set out in the Notice of Meeting dated 13 October 2023;
- Mr Jannink has previously been granted 510,660 Options for nil consideration under the Equity Incentive Plan as set out in the Company's Prospectus dated 6 December 2022;[1]
- the Performance Rights will be issued on the terms and conditions in Schedule 2 and a summary of the material terms of the Equity Incentive Plan is set out in Schedule 3;
- Performance Rights are proposed to be granted as they create share price alignment between participants and Shareholders, but do not provide participants with the full benefits of share ownership (such as dividend and voting rights) unless and until the vesting conditions are satisfied, the Performance Rights vest and are exercised;
- the Company's valuation of the Performance Rights is $1.22 per Performance Right. The value was determined using a 20-trading day VWAP of Shares up to and including 30 June 2026;
- the Performance Rights will be issued to Mr Jannink (or his nominees) as soon as practicable following the Meeting, and in any event no later than three years after the date of the Meeting;
- the Performance Rights will be issued for nil cash consideration and will be provided as an incentive component of Mr Jannink's remuneration package;
- no loan is provided by the Company in relation to the grant or exercise of Performance Rights proposed to be awarded to Mr Jannink under the Equity Incentive Plan;
- details of any Securities (including Performance Rights) issued under the Equity Incentive Plan will be published in the annual report of the Company relating to the period in which they were issued, along with a statement that approval for the issue was obtained under ASX Listing Rule 10.14; and
- any additional persons covered by ASX Listing Rule 10.14 who become entitled to participate in an issue of Securities (including Performance Rights) under the Equity Incentive Plan after this resolution is approved and who were not named in this Notice will not participate until Shareholder approval is obtained under that rule.

[1] Since the Prospectus date, the Company's Shareholders have approved a share split by which every one Share was subdivided into five Shares and all Options were adjusted in the same way in accordance with ASX Listing Rule 7.22.

### Voting Exclusion Statement

The Company will disregard any votes cast:

- in favour of this resolution by or on behalf of Mr Jannink, Ms Klose, and Mr Giuffrida or any of their associates (as defined in the ASX Listing Rules); or
- on this resolution as proxy by members of the KMP at the date of the Meeting, or their Closely Related Parties,

unless the vote is cast by:

- a person as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way;
- the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given to the Chair to vote on the resolution as the Chair decides even though this resolution is connected with the remuneration of the KMP; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided that:
  - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting and is not an associate of a person excluded from voting on the resolution; and
  - the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

### Voting Threshold

Resolution 3 is an Ordinary Resolution, which requires it to be passed by a simple majority of the votes cast by Shareholders entitled to vote on the resolution.

### Directors' Recommendation

Mr Alexander Jannink abstains from making a voting recommendation on Resolution 3 as it relates to a grant of Performance Rights to him.

The other Directors unanimously recommend that Shareholders vote in favour of this resolution.

### Chair's Voting Intention

The Chair of the Meeting intends to vote all available proxies in favour of this resolution.

## Resolution 4: Approval of Increase to Non-Executive Directors' Fee Pool

### Background

Resolution 4 seeks the approval of Shareholders in accordance with Article 15.9.1 of the Constitution and ASX Listing Rule 10.17 to increase the maximum aggregate amount payable by way of fees to non-executive directors in any financial year (NED Fee Pool). ASX Listing Rule 10.17 provides that a listed entity must not increase the NED Fee Pool without Shareholder approval. A similar requirement is included in Article 15.9.1 of the Constitution. The current NED Fee Pool is $350,000 as stipulated in clause 15.9.1 of the Constitution.

Shareholder approval is sought to increase the NED Fee Pool by $250,000 from $350,000 to $600,000 per annum. In accordance with ASX Listing Rule 10.17, the NED Fee Pool is inclusive of superannuation contributions made by the Company for the benefit of the non-executive directors and any fees which a non-executive director agrees to sacrifice for other benefits on a pre-tax basis.

The Directors have undertaken a review of the remuneration paid to non-executive directors in comparably sized companies and the Directors are seeking Shareholder approval to increase the NED Fee Pool for the following reasons:

- to allow for an increase in the number of non-executive directors on the Board, as and when required to ensure the effective guidance and monitoring of the business of the Company as it continues to grow;
- to ensure that the Company has the ability to set fees at a competitive level so that it can attract and retain the services of non-executive directors of the highest calibre as the size, complexity and risks associated with the Company have all significantly increased requiring fees to be set at commensurate levels;
- to ensure that the Company continues to maintain a high standard of corporate governance oversight; and
- to reflect market competitiveness for non-executive directors with the skills and experience that are appropriate for the Company's business.

The remuneration provided to non-executive directors is reviewed annually.

Details of non-executive director remuneration for the financial year ended 30 June 2026 are contained within the Remuneration Report in the Company's 2026 Annual Report. The total aggregate value of the remuneration provided to all non-executive directors during FY26 was $248,650. Based on the current fee schedule and Board composition, total remuneration in FY27 is expected to be approximately $300,000.

If Shareholder approval is obtained for this resolution, the NED Fee Pool will increase to $600,000 per annum. If shareholder approval is not obtained for this resolution, any potential future fee increases or appointment of an additional director would only be possible up to the amount of the existing fee cap of $350,000. This will mean that the Directors will not have the flexibility described above, and any future non-executive director appointments and fees will need to be assessed within the current NED Fee Pool.

In the preceding three years, 250,000 Options exercisable at $1.00 with an expiry date of 17 November 2028 have been issued to a non-executive director (Mr Giuffrida) under ASX Listing Rule 10.14 with Shareholder approval.

### Voting Exclusion Statement

The Company will disregard any votes cast:

- in favour of this resolution by or on behalf of Mr Mirchandani, Mr Jannink, Ms Klose, and Mr Giuffrida or any of their associates (as defined in the ASX Listing Rules); or
- on this resolution as proxy by members of the KMP as at the date of the Meeting, or their Closely Related Parties,

unless the vote is cast by:

- a person as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way;
- the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given to the Chair to vote on the resolution as the Chair decides even though this resolution is connected with the remuneration of the KMP; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided that:
  - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting and is not an associate of a person excluded from voting on the resolution; and
  - the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

### Voting Threshold

Resolution 4 is an Ordinary Resolution, which requires it to be passed by a simple majority of the votes cast by Shareholders entitled to vote on the resolution.

### Directors' Recommendation

Noting that each Director has a personal interest in their own remuneration, the Directors unanimously recommend that Shareholders vote in favour of this resolution.

### Chair's Voting Intention

The Chair of the Meeting intends to vote all available proxies in favour of this resolution.

## Resolution 5: Renewal of Proportional Takeover Bid Provisions in the Constitution

### Background

The Company's Constitution contains, at clause 27, proportional takeover bid approval provisions (PTBA Provisions) which enable the Company to refuse to register securities acquired under a proportional takeover bid unless a resolution is passed by Shareholders in a general meeting approving the offer. In accordance with the Constitution and the Corporations Act, clause 27 ceases to have effect after three years from adoption or renewal unless it is renewed. The PTBA Provisions in the current Constitution were included when the constitution was adopted and have now expired.

Resolution 5 seeks the approval of Shareholders to renew the PTBA Provisions as set out in clause 27 of the Constitution for a further three years under section 648G(4) of the Corporations Act. The Corporations Act requires the Company to provide Shareholders with an explanation of the PTBA Provisions as set out below.

### Information required by section 648G of the Corporations Act

a) *What is a proportional takeover bid?*

A proportional off-market takeover bid (PT Bid) is a takeover offer sent to all Shareholders but only for a specified portion of each Shareholder's Securities. Accordingly, if a Shareholder accepts in full the offer under a PT Bid, it will dispose of the specified portion of its securities in the Company and retain the balance of the Securities.

b) *Effect of renewal*

If renewed, under clause 27 of the Constitution if a PT Bid is made to Shareholders of the Company, the Board is required to convene a meeting of Shareholders to vote on a resolution to approve the proportional takeover. That meeting must be held at least 14 days before the offer under the PT Bid closes.

The resolution is taken to have been passed if a majority of Securities voted at the meeting, excluding the Securities of the bidder and its associates, vote in favour of the resolution. If no resolution is voted on at least 14 days before the close of the PT Bid, the resolution is deemed to have been passed. Where the resolution approving the PT Bid is passed or deemed to have been passed, transfers of Securities resulting from accepting the PT Bid are registered provided they otherwise comply with the Corporations Act, the ASX Listing Rules, the ASX Operating Rules and the Company's Constitution. If the resolution is rejected, then under the Corporations Act the PT Bid is deemed to be withdrawn.

The Directors consider that Shareholders should have the opportunity to renew the PTBA Provisions. Without the PTBA Provisions applying, a PT Bid for the Company may enable effective control of the Company to be acquired without Shareholders having the opportunity to dispose of all of their Securities to the bidder. Shareholders could be at risk of passing control to the bidder without payment of an adequate control premium for all their Securities whilst leaving themselves as part of a minority interest in the Company.

Without the PTBA Provisions, if there was a PT Bid and Shareholders considered that control of the Company was likely to pass, Shareholders would be placed under pressure to accept the PT Bid even if they did not want control of the Company to pass to the bidder. Renewing the PTBA Provisions will make this situation less likely by permitting Shareholders to decide whether a PT Bid should be permitted to proceed.

c) *No knowledge of present acquisition proposals*

As at the date of this Notice, no Director is aware of a proposal by any person to acquire, or to increase the extent of, a substantial interest in the Company.

d) *Potential advantages and disadvantages*

The renewal of the PTBA Provisions will enable the Directors to formally ascertain the views of Shareholders about a PT Bid. Without these provisions, the Directors are dependent upon their perception of the interests and views of Shareholders. Other than this advantage, the Directors consider that renewal of the PTBA Provisions has no potential advantages or potential disadvantages for them, as they remain free to make a recommendation on whether a PT Bid should be accepted.

The Directors consider that renewing the PTBA Provisions benefits all Shareholders in that they will have an opportunity to consider a PT Bid and then attend or be represented by proxy at a meeting of Shareholders called specifically to vote on the proposal. Accordingly, Shareholders are able to prevent a PT Bid proceeding if there is sufficient support for the proposition that control of the Company should not be permitted to pass under the PT Bid. Furthermore, knowing the view of Shareholders assists each individual Shareholder to assess the likely outcome of the PT Bid and whether to accept or reject that bid.

As to the possible disadvantages to Shareholders of renewing the PTBA Provisions, the proposal may make a PT Bid more difficult and PT Bids may therefore be discouraged. This may reduce the opportunities which Shareholders may have to sell all or some of their Securities at a premium to persons seeking control of the Company and may reduce any takeover speculation element in the Company's Share price. The PTBA Provisions may also be considered an additional restriction on the ability of individual Shareholders to deal freely in their Securities.

The Directors consider that there are no other advantages or disadvantages for Directors or Shareholders which arose during the period during which the PTBA Provisions were in effect, other than those discussed in this Section. On balance, the Directors consider that the possible advantages outweigh the possible disadvantages so that the renewal of the PTBA Provisions is in the interests of Shareholders.

### Voting Threshold

Resolution 5 is a Special Resolution, which requires it to be passed by at least 75% of the votes cast by Shareholders entitled to vote on the resolution.

### Directors' Recommendation

The Directors unanimously recommend that Shareholders vote in favour of this resolution.

### Chair's Voting Intention

The Chair of the Meeting intends to vote all available proxies in favour of this resolution.

## Resolution 6: Approval of 10% Additional Placement Capacity under ASX Listing Rule 7.1A

### Background

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 provides that a listed entity must not, subject to specific exceptions, issue or agree to issue Equity Securities that total more than 15% of its fully paid ordinary shares in a 12-month period without the approval of shareholders.

Listing Rule 7.1A permits eligible entities, which have obtained shareholder approval by Special Resolution passed at its annual general meeting, to increase this 15% limit by an extra 10% to a total of 25% (Additional Placement Capacity).

The Company seeks Shareholder approval under this resolution to be able to issue Equity Securities under the Additional Placement Capacity without any further Shareholder approval. If this resolution is not passed, the Company will not be able to access the Additional Placement Capacity to issue Equity Securities without Shareholder approval provided for in Listing Rule 7.1A and will remain subject to the 15% limit on issuing Equity Securities without Shareholder approval set out in Listing Rule 7.1. The exact number of Equity Securities to be issued is not fixed and will be determined in accordance with the formula prescribed in Listing Rule 7.1A.2 (set out below).

### Requirements of Listing Rule 7.1A

a) *Eligible entities*

An eligible entity for the purposes of Listing Rule 7.1A is an entity that at the date of the Meeting is not included in the S&P/ASX 300 Index and has a market capitalisation of $300 million or less.

As at 15 September 2026, the Company is an eligible entity as it is not included in the S&P/ASX 300 Index and has a current market capitalisation of approximately $199.90 million.

b) *Shareholder approval*

Shareholders must approve the Additional Placement Capacity by Special Resolution at an annual general meeting and therefore this Resolution requires approval of at least 75% of the votes cast by Shareholders entitled to vote on the Resolution. A resolution under Listing Rule 7.1A cannot be put at any other shareholder meeting.

c) *Equity Securities*

Equity Securities issued under the Additional Placement Capacity must be in the same class as an existing class of Equity Securities of the Company that are quoted on ASX.

As at the date of this Notice, the Equity Securities of the Company that are quoted on ASX are fully paid ordinary Shares.

d) *Formula for calculating number of Equity Securities that may be issued under the Additional Placement Capacity*

If this resolution is passed, the Company may issue or agree to issue, during the 12 month period after this Meeting, the number of Equity Securities calculated in accordance with the following formula under its Additional Placement Capacity:

(A x D) – E, where:

| | |
|---|---|
| A means | The number of Shares on issue 12 months before the date of issue or agreement:<br>● plus the number of Shares issued in the previous 12 months under an exception in Listing Rule 7.2 (other than exceptions 9, 16 or 17);<br>● plus the number of Shares issued in the previous 12 months on the conversion of convertible securities within rule 7.2 exception 9 where: (i) the convertible securities were issued or agreed to be issued before the commencement of the 12 month period; or (ii) the issue of, or agreement to issue, the convertible securities was approved, or taken under the Listing Rules to have been approved under Listing Rules 7.1 or 7.4;<br>● plus the number of Shares issued in the previous 12 months under an agreement to issue securities within Listing Rule 7.2 exception 16 where (i) the agreement was entered into before the commencement of the 12 month period; or (ii) the agreement or issue was approved, or taken under the Listing Rules to have been approved, under Listing Rules 7.1 or 7.4;<br>● plus the number of partly paid shares that became fully paid in the previous 12 months;<br>● plus the number of Shares issued in the previous 12 months with the approval of shareholders under Listing Rules 7.1 or 7.4; and<br>● less the number of Shares cancelled in the previous 12 months. |
| D means | 10% |
| E means | The number of Equity Securities issued or agreed to be issued under Rule 7.1A.2 in the 12 months before the date of issue or agreement to issue that has not been subsequently approved by shareholders under Listing Rule 7.4. |

## Information for Shareholders as required by Listing Rule 7.3A

a) *Minimum price*

The issue price of any Equity Securities issued under the Additional Placement Capacity will be no lower than 75% of the volume weighted average market price for securities in the relevant quoted class calculated over the 15 trading days on which trades in that class were recorded immediately before:

- the date on which the price of the Equity Securities is to be issued is agreed; or
- if the Equity Securities are not issued within 10 trading days of the date above, the date on which the Equity Securities are issued.

b) *Risk of economic and voting dilution*

If this resolution is passed and the Company issues Equity Securities under the Additional Placement Capacity, existing Shareholders' voting power in the Company will be diluted to the extent they do not receive Equity Securities under the issue.

There is the risk that:

- the market price for the Company's Equity Securities may be significantly lower on the date of issue of the new Equity Securities than on the date of the Meeting; and
- the new Equity Securities may be issued at a price that is at a discount to the market price of the Company's existing Equity Securities on the issue date, which may have an effect on the amount of Securities issued and the funds raised.

The following table shows the voting dilution impact for Equity Securities issued under the Additional Placement Capacity where the number of Shares on issue (Variable A in the formula) increases by 50% and 100% and the economic dilution where there are changes in the issue price of Shares (based on a 50% decrease to the current market price at 15 September 2026 and a 100% increase).

| Variable 'A' in Listing Rule 7.1A.2 | | Dilution | | |
|---|---|---|---|---|
| | | $0.585<br><br>50% decrease in Issue Price | $1.17<br><br>Issue Price | $2.34<br><br>100% increase in Issue Price |
| Current Variable A 170,853,613 Shares | 10% Voting Dilution | 17,085,361 Shares | 17,085,361 Shares | 17,085,361 Shares |
| | Funds raised | $9,994,936 | $19,989,872 | $39,979,745 |
| 50% increase in Variable A 256,280,420 Shares | 10% Voting Dilution | 25,628,042 Shares | 25,628,042 Shares | 25,628,042 Shares |
| | Funds raised | $14,992,405 | $29,984,809 | $59,969,618 |
| 100% increase in Variable A 341,707,226 Shares | 10% Voting Dilution | 34,170,723 Shares | 34,170,723 Shares | 34,170,723 Shares |
| | Funds raised | $19,989,873 | $39,979,746 | $79,959,492 |

This table has been prepared on the following assumptions:

i. The total number of Shares on issue at 15 September 2026 is 170,853,613.

ii. The issue price is $1.17, being the closing price of the Shares on ASX on 15 September 2026.

iii. The Company issues the maximum number of Equity Securities available under the Additional Placement Capacity.

iv. The Company has not issued any Equity Securities in the 12 months prior to the Meeting that were not issued under an exception in Listing Rule 7.2 or with Shareholder approval.

v. No Options or Performance Rights are exercised into Shares before the date of the issue of the Equity Securities under the Additional Placement Capacity.

vi. The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the Additional Placement Capacity, based on that Shareholder's holding at the date of the Meeting.

vii. The table shows only the effect of issues of Equity Securities under Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1.

viii. The issue of Equity Securities under the Additional Placement Capacity consists only of Shares.

ix. Numbers have been rounded to the nearest whole number.

c) *Placement Period*

Shareholder approval of the Additional Placement Capacity under Listing Rule 7.1A is valid from 28 October 2026 (the date of this Meeting) and expires on the earlier of:

- 27 October 2027, which is 12 months after this Meeting;
- the time and date of the Company's next annual general meeting; or
- the date that Shareholders approve a transaction under Listing Rule 11.1.2 (significant change to nature or scale of activities) or 11.2 (disposal of the main undertaking).

The Company will only issue and allot new Equity Securities under the Additional Placement Capacity during the Placement Period.

d) *Purposes for which the new Equity Securities may be issued*

The Company may seek to issue new Equity Securities to raise funds for the continued development of the Company's current assets, the acquisition of new assets or investments (including the expenses associated with such acquisition) and for general working capital.

e) *Allocation policy*

Additional Placement Capacity will depend on the market conditions existing at the time of the proposed issue. The allottees will be determined at the relevant time having regard to factors such as:

- the purpose of the issue;
- the methods of raising funds that are available to the Company, including, but not limited to, a placement or a rights issue;
- the effect of the issue of new securities on the control of the Company;
- the financial situation and solvency of the Company; and
- advice from corporate, financial and broking advisers (as relevant).

As at the date of this Notice, the allottees are not known but may include existing substantial Shareholders and/or new Shareholders. No allottee under the Additional Placement Capacity will be a related party or associate of a related party. Existing Shareholders may or may not be entitled to subscribe for any Equity Securities issued under the Additional Placement Capacity and it is possible that their shareholding will be diluted.

The Company will comply with the disclosure obligations under Listing Rule 7.1A.4 on the issue of any new securities under the Additional Placement Capacity.

f) *Previous approval under Listing Rule 7.1A*

The Company previously obtained approval from its Shareholders pursuant to Listing Rule 7.1A (Previous Approval) at its annual general meeting held on 19 November 2025 (2025 AGM).

During the period from the 2025 AGM to the date of the Meeting, the Company has issued 13,107,713 Shares pursuant to the Previous Approval (Previous Issue), which represented approximately 9.22% of the total diluted number of Equity Securities on issue in the Company on 19 November 2025, which was 142,188,251.

Further details of the issue of Equity Securities by the Company pursuant to Listing Rule 7.1A.2 during the period from the 2025 AGM to the date of the Meeting are set out below.

The following information is provided in accordance with Listing Rule 7.3A.6(b) in respect of the Previous Issue:

| | |
|---|---|
| Date of Issue and Appendix 2A | Date of Issue: 22 December 2025<br>Date of Appendix 2A: 19 December 2025 |
| Recipients | Professional and sophisticated investors as part of a placement announced on 15 December 2025. The placement participants were identified through a bookbuild process managed by Morgans Corporate Limited and Canaccord Genuity (Australia) Limited (together, the Joint Lead Managers). |
| Number and Class of Equity Securities Issued | 13,107,713 Shares |
| Issue Price and discount | $1.50 per Share (at a discount of 11.24% to the closing price on 22 December 2025) |
| Total Cash Consideration and Use of Funds | Amount raised: $30,000,000 (total amount raised under the placement, including from Shares issued under both Listing Rules 7.1 and 7.1A)<br>Amount spent: Approximately $14,000,000<br>Use of funds: The funds have been used for:<br>● business development purposes;<br>● contract mobilisation and purchase of fixed assets;<br>● existing and new product innovation;<br>● working capital purposes;<br>● litigation related costs; and<br>● costs of the placement.<br>Amount remaining: Approximately $16,000,000<br>Proposed use of remaining funds[2]:<br>● business development purposes;<br>● contract mobilisation and purchase of fixed assets;<br>● existing and new product innovation; and<br>● working capital purposes. |

As at the date of this Notice, the Company has not identified or invited any person to participate in an issue of Equity Securities under Listing Rule 7.1A. Therefore, no existing Shareholders will be excluded from voting on this resolution.

### Voting Threshold

Resolution 6 is a Special Resolution, which requires it to be passed by at least 75% of the votes cast by Shareholders entitled to vote on the resolution.

### Directors' Recommendation

The Directors unanimously recommend that Shareholders vote in favour of this resolution.

### Chair's Voting Intention

The Chair of the Meeting intends to vote all available proxies in favour of this resolution.

## Notice to Persons outside Australia

This Notice of Meeting, including the Explanatory Statement, has been prepared in accordance with Australian laws, disclosure requirements and accounting standards, which may differ from those in other countries. The distribution of the Notice of Meeting, including the Explanatory Statement, may be restricted by law or regulation in certain countries. Therefore, persons who come into possession of the Notice of Meeting, including the Explanatory Statement, should inform themselves of any such restrictions and comply accordingly.

[2] This is a statement of current intentions as at the date of this Notice. As with any budget, intervening events and new circumstances have the potential to affect the manner in which the funds are ultimately applied. The Board reserves the right to alter the way the funds are applied on this basis.

# SCHEDULE 1 – GLOSSARY

**Annual General Meeting or AGM or Meeting** means the meeting convened by this Notice of Meeting.

**ASX** means ASX Limited (ACN 620 466 248).

**ASX Listing Rules** means the Listing Rules of the ASX.

**Auditor's Report** means the auditor's report of BDO Audit Pty Ltd as included in the 2026 Annual Report.

**Board** means the current Board of Directors of the Company.

**CEO** means Chief Executive Officer.

**Closely Related Party** has the meaning as defined in section 9 of the Corporations Act.

**Company** means Acusensus Limited (ACN 625 231 941).

**Constitution** means the Company's constitution.

**Corporations Act** means the Corporations Act 2001 (Cth).

**Director** means a current director of the Company.

**Directors' Report** means the report of Directors as included in the 2026 Annual Report.

**Entitlement Time** means 7:00pm (Sydney time) on Monday, 26 October 2026.

**Equity Incentive Plan or Plan** means the Acusensus Equity Incentive Plan Rules last approved at the Company's 2025 Annual General Meeting as set out in the Notice of Meeting dated 17 October 2025.

**Equity Securities** has the meaning as defined in the ASX Listing Rules.

**Explanatory Statement** means the Explanatory Statement accompanying, and forming part of, this Notice of Meeting.

**Financial Report** means the financial statements of the consolidated entity consisting of Acusensus Limited and its controlled entities.

**FY26** means the financial year ended 30 June 2026.

**HIN** means Holder Identification Number.

**Key Management Personnel or KMP** has the meaning as defined in section 9 of the Corporations Act.

**MUFG Corporate Markets (AU) Limited** means the Company's share registry.

**Notice or Notice of Meeting** means this Notice of Annual General Meeting, including the Explanatory Statement and Proxy Form accompanying this Notice of Meeting.

**Option** means an option issued under the Equity Incentive Plan.

**Ordinary Resolution** means a resolution that must be passed by more than 50% of the total votes cast by Shareholders entitled to vote on that resolution.

**Performance Right** means a performance right issued under the Equity Incentive Plan.

**Proxy Deadline** means 10:30am (Sydney time) on Monday, 26 October 2026.

**Proxy Form** means the proxy form accompanying this Notice of Meeting.

**Remuneration Report** means the remuneration report set out in the Directors' Report section of the Company's 2026 Annual Report.

**Securities** means Shares, Options or Performance Rights (as the context requires).

**Share** means a fully paid ordinary share in the capital of the Company.

**Shareholder** means a registered holder of a Share.

**Special Resolution** means a resolution that must be passed by at least 75% of the total votes cast by Shareholders entitled to vote on that resolution.

**SRN** means Shareholder Reference Number.

**Sydney time** means Australian Eastern Daylight Time as observed in Sydney, Australia.

**VWAP** means volume weighted average price.

**2026 Annual Report** means the Company's annual report to Shareholders for the period ended 30 June 2026 as lodged by the Company with the ASX on 25 August 2026.

# SCHEDULE 2 – SUMMARY OF TERMS AND CONDITIONS OF PERFORMANCE RIGHTS

1. (Entitlement): Subject to the terms and conditions set out below, each Performance Right, once vested, entitles the holder on exercise to be:
   a) allocated one fully paid ordinary share in the capital of the Company (Share) (unless an adjustment to that number is made under these terms, in which case the holder is entitled to the adjusted number); or
   b) paid the 'volume weighted average market price' (as that term is defined in the Listing Rules) of the Shares the holder would otherwise have been entitled to receive under term 1(a) (calculated during the five trading days before exercise of the Performance Right) (Market Value),

   as determined by the Board in its absolute discretion.
2. (Issue Price): The Performance Rights are issued for nil cash consideration.
3. (Vesting Conditions and Performance Hurdles): Subject to the terms and conditions set out below, the Performance Rights will have the Vesting Conditions and Performance Hurdles specified below. The Performance Rights will vest on the Company notifying the holder that the Vesting Conditions and Performance Hurdles have been satisfied (or to the extent permitted by the Plan and at the Board's ultimate discretion, waived).

| Number | Vesting Condition | Performance Hurdle |
|---|---|---|
| 36,202 | 12 months from 30 June 2026 | TSR[3]: 0-10% |
| 36,202 | | GP uplift[4]: Based on the gross profit achieved against the FY26 gross profit with a fixed percentage target set for each year of the three-year vesting period. |
| 36,202 | 12 months from 30 June 2026 | TSR[3]: 0-20% |
| 36,202 | | GP uplift[4]: Based on the gross profit achieved against the FY26 gross profit with a fixed percentage target set for each year of the three-year vesting period. |
| 36,202 | 12 months from 30 June 2026 | TSR[3]: 0-30% |
| 36,203 | | GP uplift[4]: Based on the gross profit achieved against the FY26 gross profit with a fixed percentage target set for each year of the three-year vesting period. |
| 217,213 | TOTAL | |

   The Vesting Condition requires the holder to remain employed or otherwise engaged by the Company or a subsidiary of the Company at all times between the date of issue of the Performance Rights and the date described in the Vesting Condition.
4. (Vesting): Subject to the satisfaction of the applicable Vesting Condition and Performance Hurdle, the Company will notify the holder in writing (Vesting Notice) as soon as reasonably practicable that the relevant Vesting Conditions have been satisfied and the outcome of the Performance Hurdles.
5. (Expiry Date): The Performance Rights will expire and lapse on the first to occur of the following:
   a) the Vesting Condition and/or Performance Hurdle becoming incapable of satisfaction due to the cessation of employment or other engagement of the holder with the Company (or any of its subsidiaries) (subject to the exercise of the Board's discretion under the Plan); and
   b) 5:00pm on the date which is 5 years after the date of issue of the Performance Rights,

[3] TSR (Total Shareholder Return) refers to the value of the Company's shares plus any dividend paid above the 20-day VWAP price ending 30 June 2026 of $1.22.
[4] GP uplift refers to increase on FY26 gross profit of $36.2m.

(Expiry Date).

6. (Exercise): At any time between receipt of a Vesting Notice and the Expiry Date (as defined in clause 5 above), the holder may apply to exercise Performance Rights by delivering a notice of exercise to the Company Secretary or the Company's share registry (as directed by the Company). The holder is not required to pay a fee to exercise the Performance Rights.
7. (Allocation of Shares): As soon as practicable after the exercise of a vested Performance Right, the Company will at its election:
   a) either:
      i) issue, allocate or cause to be transferred to the holder the number of Shares to which the holder is entitled; and
      ii) if necessary, do all such acts, matters and things to obtain the grant of quotation of the Shares by ASX in accordance with the Listing Rules; or
   b) pay the holder the Market Value of the Shares the holder would otherwise be entitled to under term 7(a)(i).
8. (Ranking): All Shares issued upon the conversion of Performance Rights will upon issue rank equally in all respects with other Shares.
9. (Transferability of the Performance Rights): The Performance Rights are not transferable, except with the prior written approval of the Company at its sole discretion and subject to compliance with the Corporations Act and Listing Rules.
10. (Dividend rights): A Performance Right does not entitle the holder to any dividends.
11. (Voting rights): A Performance Right does not entitle the holder to vote on any resolutions proposed at a general meeting of the Company, subject to any voting rights provided under the Corporations Act or the Listing Rules where such rights cannot be excluded by these terms.
12. (Quotation of the Performance Rights) The Company will not apply for quotation of the Performance Rights on any securities exchange.
13. (Adjustments for reorganisation): If there is any reorganisation of the issued share capital of the Company, the rights of the Performance Rights holder will be varied in accordance with the Listing Rules.
14. (Entitlements and bonus issues): Subject to the rights under clause 15 below, holders will not be entitled to participate in new issues of capital offered to shareholders such as bonus issues and entitlement issues. There will be no change to the number of Shares over which the Performance Rights are exercisable in the event of the Company making a pro-rata issue of Shares or other securities to the holders of Shares in the Company (other than a bonus issue).
15. (Bonus issues): If the Company makes a bonus issue of Shares or other securities to existing Shareholders (other than an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment), the number of Shares which the holder is entitled to be allocated on the exercise of a vested Performance Right (or the number of Shares which will be used for the purpose of determining the Market Value if the Board determines that the holder is to be paid the Market Value) will be increased by the number of Shares which the holder would have received if the holder had exercised the Performance Right before the record date for the bonus issue.
16. (Forfeiture): If the Board determines that an event described in term 17 below has occurred:
   a) all unvested and vested Performance Rights held by the holder will automatically lapse in accordance with clause 13.1.2 of the Plan; and
   b) the Board may, in its absolute discretion and subject to Applicable Law and the terms of a holder's employment contract, exercise its discretion to adjust or further adjust a holder's Award or remuneration. If the Board exercises that discretion:
      i) the number of Shares provided to the holder on exercise of Performance Rights determined by the Board will be surrendered in accordance with clause 14 of the Plan;

ii) the holder will be required to transfer to the trustee of any employee share trust established in connection with the Plan the number of Shares provided to the holder on exercise of Performance Rights determined by the Board (and the holder authorises the Company to effect that transfer on their behalf);

iii) the holder will be required to repay the Company an amount determined by the Board;

iv) there will be a reduction in the holder's future pay of such amount determined by the Board; and/or

v) there will be any other form of alteration of the holder's remuneration determined by the Board.

17. (Forfeiture Conditions): the following events apply for the purpose of term 16:

a) the holder has committed any serious or persistent breach of the provisions of any contract or deed entered into by the holder with any Group Company;

b) the holder has engaged in fraudulent or dishonest conduct in the performance of the holder's duties or in any behaviour that may materially impact on the Group's reputation or long-term financial strength;

c) the holder has committed any wrongful or negligent act or omission which has caused any Group Company substantial liability;

d) the holder has become disqualified from managing corporations in accordance with Part 2D.6 of the Corporations Act or has committed any act that may result in the holder being banned from managing a corporation under the Corporations Act; or

e) the Participant has engaged in serious or gross misconduct, wilful disobedience, or gross negligence;

f) the financial results that led to the Performance Rights being granted are subsequently shown to be materially misstated;

g) an event occurs that results in the Group being required or entitled under law to reclaim remuneration from a holder; or

h) there is a significant and unintended deterioration in the financial performance of the Group resulting directly or indirectly from an act or omission of the holder.

18. (Return of capital rights): The Performance Rights do not confer any right to a return of capital, whether in a winding up, upon a reduction of capital or otherwise.

19. (Rights on winding up): The Performance Rights have no right to participate in the surplus profits or assets of the Company upon a winding up of the Company.

20. (Takeovers prohibition):

a) the issue of Shares on exercise of the Performance Rights is subject to and conditional upon the issue of the relevant Shares not resulting in any person being in breach of section 606(1) of the Corporations Act; and

b) the Company will not be required to seek the approval of its members for the purposes of Item 7 of section 611 of the Corporations Act to permit the issue of any Shares on exercise of the Performance Rights.

21. (No other rights) A Performance Right does not give a holder any rights other than those expressly provided by these terms and those provided at law where such rights at law cannot be excluded by these terms.

22. (Amendments required by ASX) The terms of the Performance Rights may be amended as set out in the Plan, including as considered necessary by the Board in order to comply with the Listing Rules, or any directions of ASX regarding the terms provided that, subject to compliance with the Listing Rules, following such amendment, the economic and other rights of the holder are not materially reduced.

23. (Plan) The Performance Rights are issued pursuant to and are subject to the Plan. In the event of conflict between a provision of these terms and conditions and the Plan, these terms and conditions prevail to the extent of that conflict.

# SCHEDULE 3 – SUMMARY OF EQUITY INCENTIVE PLAN

1. The Equity Incentive Plan (Plan) is open to "Eligible Participants", being
   a) an 'ESS Participant' (as that term is defined in section 1100L of the Corporations Act) in relation to the Company or an Associated Entity of the Company, where that Associated Entity is a body corporate; and
   b) has been determined by the Board to be eligible to participate in the Plan from time to time.
2. Under the rules of the Equity Incentive Plan, the Board has discretion to offer any of the following awards:
   a) options to acquire Shares;
   b) performance rights to be issued Shares (or be paid the market value of the Shares); and/or
   c) Shares, including Shares to be acquired under a limited recourse loan funded arrangement,

   in each case subject to vesting conditions and/or performance hurdles as determined by the Board (collectively, the Awards).
3. The Board may determine the type and number of Awards to be issued under the Equity Incentive Plan to each Eligible Participant and other terms of issue of the Awards, including, but not limited to:
   a) the conditions and/or performance hurdles that must be met by a participant in order for an Award to vest (if any);
   b) the fee to be paid by a participant on the grant of Awards (if any);
   c) the exercise price of any option granted to a participant;
   d) the period during which a vested option can be exercised; and
   e) any forfeiture conditions or disposal restrictions applying to the Awards and any Shares that a participant receives upon exercise of their options or vesting of performance rights.
4. The Board may, in its discretion, also determine that the Company will issue limited recourse loans to Eligible Participants to use for the purchase of Shares as part of a Share Award under the Plan.
5. When any conditions and/or performance hurdles have been satisfied, participants will receive fully vested Shares or their options/performance rights will become vested and will be exercisable into Shares (as applicable).
6. Each vested option and performance right enables the participant to be issued or to be transferred one Share upon exercise or vesting (as applicable) or to be paid the applicable market value of the Shares that the participant would otherwise have been entitled to receive upon exercise, as determined by the Board in its absolute discretion and subject to the rules governing the Equity Incentive Plan and the terms of any particular offer.
7. Participants holding options or performance rights are not permitted to participate in new issues of Securities by the Company but adjustments may be made to the number of Shares over which the options or performance rights are granted and/or the exercise price (if any) to take into account changes in the capital structure of the Company that occur by way of pro rata and bonus issues in accordance with the rules of the Equity Incentive Plan and the ASX Listing Rules.
8. In the event of a change of control of the Company, subject to the ASX Listing Rules, an Award will vest to the extent determined by the Board.
9. The Board may determine that upon a participant becoming a Good Leaver (as defined in the rules of the Equity Incentive Plan), the Awards of that participant may vest early or any holding period applicable to those Awards may be waived or reduced. In relation to a Bad Leaver (as defined in the rules of the Equity Incentive Plan), unless the Board determines otherwise, unvested options and performance rights will automatically lapse and unvested Awards and loan funded shares will automatically be surrendered.
10. The Board may delegate management and administration of the Equity Incentive Plan, together with any of their powers or discretions under the Plan, to a committee of the Board or to any one or more persons selected by them as the Board thinks fit.

acusensus

ACN 625 231 941

## LODGE YOUR VOTE

**ONLINE**
https://au.investorcentre.mpms.mufg.com

**BY MAIL**
Acusensus Limited
C/- MUFG Corporate Markets (AU) Limited
Locked Bag A14
Sydney South NSW 1235 Australia

**BY FAX**
+61 2 9287 0309

**BY HAND**
MUFG Corporate Markets (AU) Limited
Parramatta Square, Level 22, Tower 6,
10 Darcy Street, Parramatta NSW 2150

**ALL ENQUIRIES TO**
Telephone: 1300 554 474 Overseas: +61 1300 554 474

X99999999999



# PROXY FORM

I/We being a member(s) of Acusensus Limited and entitled to attend and vote hereby appoint:

## STEP 1

## APPOINT A PROXY

☐ **the Chair of the Meeting (mark box)**

**OR** if you are **NOT** appointing the Chair of the Meeting as your proxy, please write the name of the person or body corporate you are appointing as your proxy

or failing the person or body corporate named, or if no person or body corporate is named, the Chair of the Meeting, as my/our proxy to act on my/our behalf (including to vote in accordance with the following directions or, if no directions have been given and to the extent permitted by the law, as the proxy sees fit) at the Annual General Meeting of the Company to be held at **10:30am (Sydney time) on Wednesday, 28 October 2026 at Cliftons Sydney Margaret Street, 13/60 Margaret Street, Sydney NSW 2000, Australia** (the **Meeting**) and at any postponement or adjournment of the Meeting.

**Important for Items 1, 3 & 4:** If the Chair of the Meeting is your proxy, either by appointment or by default, and you have not indicated your voting intention below, you expressly authorise the Chair of the Meeting to exercise the proxy in respect of Items 1, 3 & 4, even though the Items are connected directly or indirectly with the remuneration of a member of the Company's Key Management Personnel (**KMP**).

**The Chair of the Meeting intends to vote undirected proxies in favour of each item of business.**

## STEP 2

## VOTING DIRECTIONS

**Proxies will only be valid and accepted by the Company if they are signed and received no later than 48 hours before the Meeting.**

**Please read the voting instructions overleaf before marking any boxes with an ☒**

### Items

| Item | For | Against | Abstain* |
|---|---|---|---|
| 1 Remuneration Report (non-binding resolution) | | | |
| 2 Re-election of Independent Non-Executive Director, Mr Michael Giuffrida | | | |
| 3 Grant of Performance Rights to Managing Director and CEO, Mr Alexander Jannink | | | |
| 4 Approval of Increase to Non-Executive Directors' Fee Pool | | | |
| 5 Renewal of Proportional Takeover Bid Provisions in the Constitution | | | |
| 6 Approval of 10% Additional Placement Capacity under ASX Listing Rule 7.1A | | | |

* If you mark the Abstain box for a particular Item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your votes will not be counted in computing the required majority on a poll.

## STEP 3

## SIGNATURE OF SHAREHOLDERS – THIS MUST BE COMPLETED

| Shareholder 1 (Individual) | Joint Shareholder 2 (Individual) | Joint Shareholder 3 (Individual) |
|---|---|---|
| | | |
| Sole Director and Sole Company Secretary | Director/Company Secretary (Delete one) | Director |

This form should be signed by the shareholder. If a joint holding, either shareholder may sign. If signed by the shareholder's attorney, the power of attorney must have been previously noted by the registry or a certified copy attached to this form. If executed by a company, the form must be executed in accordance with the company's constitution and the *Corporations Act 2001* (Cth).

# HOW TO COMPLETE THIS SHAREHOLDER PROXY FORM

### YOUR NAME AND ADDRESS

This is your name and address as it appears on the Company's share register. If this information is incorrect, please make the correction on the form. Shareholders sponsored by a broker should advise their broker of any changes. **Please note: you cannot change ownership of your shares using this form.**

### APPOINTMENT OF PROXY

If you wish to appoint the Chair of the Meeting as your proxy, mark the box in Step 1. If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that individual or body corporate in Step 1. A proxy need not be a shareholder of the Company.

### DEFAULT TO CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote those proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Form, including where the Items are connected directly or indirectly with the remuneration of KMP.

### VOTES ON ITEMS OF BUSINESS – PROXY APPOINTMENT

You may direct your proxy how to vote by placing a mark in one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as they choose. If you mark more than one box on an item your vote on that item will be invalid.

### APPOINTMENT OF A SECOND PROXY

You are entitled to appoint up to two persons as proxies to attend the Meeting and vote on a poll. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by telephoning the Company's share registry or you may copy this form and return them both together.

To appoint a second proxy you must:

(a) on each of the first Proxy Form and the second Proxy Form state the percentage of your voting rights or number of shares applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded; and

(b) return both forms together.

### SIGNING INSTRUCTIONS

You must sign this form as follows in the spaces provided:

**Individual:** where the holding is in one name, the holder must sign.

**Joint Holding:** where the holding is in more than one name, either shareholder may sign.

**Power of Attorney:** to sign under Power of Attorney, you must lodge the Power of Attorney with the registry. If you have not previously lodged this document for notation, please attach a certified photocopy of the Power of Attorney to this form when you return it.

**Companies:** where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the *Corporations Act 2001*) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please indicate the office held by signing in the appropriate place.

### CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate "Certificate of Appointment of Corporate Representative" must be received at support@cm.mpms.mufg.com prior to admission in accordance with the Notice of Annual General Meeting. A form of the certificate may be obtained from the Company's share registry or online at www.mpms.mufg.com/en/mufg-corporate-markets.

### LODGEMENT OF A PROXY FORM

This Proxy Form (and any Power of Attorney under which it is signed) must be received at an address given below by **10:30am (Sydney time) on Monday, 26 October 2026,** being not later than 48 hours before the commencement of the Meeting. Any Proxy Form received after that time will not be valid for the scheduled Meeting.

Proxy Forms may be lodged using the reply paid envelope or:

**ONLINE**
https://au.investorcentre.mpms.mufg.com

Login to the Investor Centre using the holding details as shown on the Voting/Proxy Form. Select 'Voting' and follow the prompts to lodge your vote. To use the online lodgement facility, shareholders will need their "Holder Identifier" - Securityholder Reference Number (SRN) or Holder Identification Number (HIN).

**BY MOBILE DEVICE**

**QR Code**

Our voting website is designed specifically for voting online. You can now lodge your vote by scanning the QR code adjacent or enter the voting link **https://au.investorcentre.mpms.mufg.com** into your mobile device. Log in using the Holder Identifier and postcode for your shareholding.

To scan the code you will need a QR code reader application which can be downloaded for free on your mobile device.

**BY MAIL**
Acusensus Limited
C/- MUFG Corporate Markets (AU) Limited
Locked Bag A14
Sydney South NSW 1235
Australia

**BY FAX**
+61 2 9287 0309

**BY HAND**
delivering it to MUFG Corporate Markets (AU) Limited*
Parramatta Square
Level 22, Tower 6
10 Darcy Street
Parramatta NSW 2150

*During business hours Monday to Friday (9:00am - 5:00pm)

**IF YOU WOULD LIKE TO ATTEND AND VOTE AT THE ANNUAL GENERAL MEETING, PLEASE BRING THIS FORM WITH YOU.**
**THIS WILL ASSIST IN REGISTERING YOUR ATTENDANCE.**

28 September 2026

Dear Shareholder

**Notice of 2026 Annual General Meeting of Acusensus Limited**

I am pleased to provide you with the details of the 2026 Annual General Meeting of Acusensus Limited (ACN 625 231 941) (**Company**), scheduled to be held on Wednesday, 28 October 2026 at 10:30am (Sydney time) (**Meeting**).

The Notice of Annual General Meeting and the accompanying Explanatory Statement (**Notice of Meeting**) and the Company's 2026 Annual Report are available for you to view and download on the Company's website at investors.acusensus.com/investor-centre/.

The Meeting will be held at Cliftons Sydney Margaret Street, 13/60 Margaret Street, Sydney NSW 2000, Australia. We encourage you to arrive at the Meeting venue from 30 minutes prior to the commencement of the Meeting to allow adequate time for registration. All shareholders are encouraged to participate in the Meeting. Instructions on how to attend the Meeting and how to vote are included in the Notice of Meeting.

If you cannot attend the Meeting in person, you are invited to watch the live webcast online and can register to do this via the instructions in the Notice of Meeting. If you choose to watch the Meeting via the webcast, or if you cannot attend the Meeting, any proxy appointments and questions will need to be submitted prior to the Meeting by following the instructions in the Notice of Meeting. Shareholders who watch the Meeting online will not be able to vote or participate in the discussions at the Meeting.

If you wish to appoint a proxy to vote on your behalf, please complete and return the enclosed proxy form. Please note your proxy must be lodged no later than 48 hours prior to the Meeting (10:30am (Sydney time) on Monday, 26 October 2026).

Also enclosed with this letter is a form that enables you to receive electronic communications from the Company. We encourage you to complete this to assist the Company to reduce the number of letters that are mailed out to its shareholders.

If you have any queries regarding how to cast your vote or other procedural questions, please call the Company's share registry, MUFG Corporate Markets (AU) Limited, on 1300 554 474 or +61 1300 554 474 (from outside Australia) between 8:30am and 7:30pm (Sydney time).

We look forward to welcoming you to the Meeting.

Yours sincerely

Annie Mould
Company Secretary
**Acusensus Limited**

ACUSENSUS LIMITED
Level 1, 31 Queen Street
Melbourne VIC 3000
Phone: 1300 214 697
info@acusensus.com
acusensus.com